Navigation Links
First NIH-funded personalized drug development center in US will focus on muscle disease
Date:10/5/2011

ch at Children's National Medical Center and the CORT's co-principal investigator. "Patients with DMD have different mutations on various exons, so finding a treatment that is effective for the majority of patients involves looking at multiple defects simultaneously, which is what the Center aims to do."

Pursuit of AO drug development extends more than 20 years, particularly focused in cancer and inflammatory disease, although success in clinical trials has been limited. "We are seeing this type of therapeutic approach working better in DMD than other indications because of improved drug delivery, and more effective molecular targeting," noted Paula Clemens, MD, associate professor of neurology at the University of Pittsburgh and co-principal investigator of the new center. Dr. Qi Lu, director of McColl Lockwood Laboratory at Carolinas Medical Center and co-investigator of the CORT, provided additional rationale for improved efficacy in DMD: "We may need to reach only 20 percent of RNA targets in a successful 'rescue' application such as in DMD, whereas the previous 'knock-down' approaches in cancer and immunological disorders had to hit 90 percent of molecular targets." Dr. Lu's research in the new CORT will help optimize drugs to achieve the highest therapeutic potential for the majority of applicable DMD patients.

Research projects sponsored by the Center will include the first natural history study of Becker muscular dystrophy, a milder form of disease that is caused by mutations in the dystrophin gene. By studying specific mutations that cause Becker muscular dystrophy, CORT researchers will gain insights into the therapeutic potential of exon-skipping approaches. A second project will look at the biochemical function of the dystrophin proteins produced through application of the different exon-skipping dru
'/>"/>

Contact: Emily Hartman
ehartman@childrensnational.org
202-476-4500
Children's National Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. New way to make malaria medicine also first step in finding new antibiotics
2. Complete Genomics launches, becomes worlds first large-scale human genome sequencing company
3. Digital zebrafish embryo provides the first complete developmental blueprint of a vertebrate
4. Synaptics to Report First Quarter Results on October 23
5. Alzheimers disease research attracts first partner
6. Volcanoes may have provided sparks and chemistry for first life
7. Study of polar dinosaur migration questions whether dinosaurs were truly the first great migrators
8. Synaptics Reports Record Results for First Quarter of Fiscal 2009
9. First comprehensive genomic study of common cold reveals new treatment targets
10. Scientists achieve first tracking of salmon from headwaters in Rockies through Pacific to Alaska
11. First results from hospital trials testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2015)... 2015 At its 2015 ACMG Annual Clinical ... , the American College of Medical Genetics and Genomics ... its Board.  Members of the ACMG Board of Directors ... and advancing its policies and programs. ACMG is the ... "It,s an eventful time in medical genetics and genomics.  ...
(Date:4/1/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces the second shipment of a ... early access pre-order customers. Feedback from ... including Walmart, Target, AT&T, Dunkin, Donuts, Stop & Shop ... all outlets and very easy to use. Several users ...
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... is also available in Spanish . , ... levels becomes accustomed to the presence of an exogenous surplus, ... source--in this case, alcohol. , According to a study by ... the University of Granada , although there are no ...
... 2007 UT Southwestern Medical Center researchers have found that ... excludes a group of obese patients at risk of cardiovascular ... of the journal Surgery for Obesity and Related Diseases, ... between body mass index (BMI) and cardiovascular disease as it ...
... to induce cells to form parallel tube-like structures that could ... researchers found that they can control the cells, development by ... on the work was posted this month in an online ... one day be transplanted into tissues such as the kidneys, ...
Cached Biology News:A research of the UGR shows the genetic predisposition to develop alcohol abuse 2BMI criteria for obesity surgery should be lowered, UT Southwestern researcher suggests 2MIT works toward engineered blood vessels 2
(Date:5/1/2015)... , May 1, 2015 Pfenex ... engaged in the development of biosimilar therapeutics including ... today that its first quarter 2015 financial results ... before the open of market. At 8:30 am Eastern ... to discuss the financial results and provide a ...
(Date:5/1/2015)... , May 1, 2015 ... Production Market by Product (Equipment, Consumables), by Type (Monoclonal, ... Diagnostic Labs, Research Institutes) - Analysis & Global ... studies the global Antibody Production Market for the ... is expected to reach $2.572 Billion by 2019 ...
(Date:4/30/2015)... CA (PRWEB) April 30, 2015 Cytokinetics, Incorporated ... first quarter of 2015 were $4.4 million, compared to $8.0 ... loss for the first quarter was $8.9 million, or $0.23 ... net loss for the same period in 2014, of $8.7 ... of March 31, 2015, cash, cash equivalents and investments totaled ...
(Date:4/30/2015)... Budapest, Hungary (PRWEB) April 30, 2015 ... electronic lab notebook with integrated protocols and specimen ... chemistry software solutions and consulting services for life ... the development of Labguru’s newest feature: chemical structure ... deep domain features for biologists, bio-chemists, and more, ...
Breaking Biology Technology:Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2
... , , MONTREAL , Jan. ... successful completion of a dose-ranging Phase 1 study and the ... combination with sorafenib for the treatment of patients with advanced ... "A Phase 2, Open-Label Study of The X-Linked Inhibitor of ...
... , , SHANGHAI ... Ltd., a,leading pharmaceutical R&D outsourcing Service Company in China ... Minster Jean-Pierre,Raffarin visited Sundia on January 22, 2010 . ... by Dr. Serge,Feneuille and Mr. Erwan Davoux ...
... LEIDEN, The Netherlands , January 26 ... are extremely,valuable for pharmaceutical research in the Netherlands . ... Top Institute, which was published today. In,the report, an independent ... is well on its way to achieving the objectives that ...
Cached Biology Technology:Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma 2Former French Prime Minister Jean-Pierre Raffarin Visits Sundia 2Veerman Committee Argues for Continuation of TI Pharma 2
Human/Mouse APLP-1 MAb (Clone 354020) ENTREZ GeneID: 333...
Mouse monoclonal [Flt-1/EWC] to VEGF Receptor 1 ( Abpromise for all tested applications). entrezGeneID: 2321 SwissProtID: P17948...
Mitotic Kinesin-Like Protein 1 (MKLP-1, KNSL5)...
Mouse Anti-Human MCAF-(MCP-1)...
Biology Products: